Ultragenyx Pharmaceutical Inc. (RARE) financial statements (2021 and earlier)

Company profile

Business Address 60 LEVERONI COURT
NOVATO, CA 94949
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,202755460234380437187
Cash and cash equivalents7144341131001619424
Short-term investments488322346134219343163
Restricted cash and investments1100010 
Receivables2333135   
Inventory, net of allowances, customer advances and progress billings131271   
Inventory131271   
Other undisclosed current assets4751432920136
Total current assets:1,295851522270402450193
Noncurrent Assets
Operating lease, right-of-use asset4130
Property, plant and equipment744420221773
Long-term investments and receivables115 1011899 
Long-term investments115 1011899 
Intangible assets, net (including goodwill)176173174186   
Goodwill44444444   
Intangible assets, net (excluding goodwill)131129129142   
Restricted cash and investments22 2221
Other noncurrent assets9341211
Other undisclosed noncurrent assets15325     
Total noncurrent assets:4642841972211391095
TOTAL ASSETS:1,7601,135720491541560198
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities121967570602817
Accounts payable1313129535
Accrued liabilities10883626155258
Employee-related liabilities      4
Deferred revenue67 
Debt07     
Deferred revenue and credits1000
Other undisclosed current liabilities1     (4)
Total current liabilities:1901037571602813
Noncurrent Liabilities
Long-term debt and lease obligation3930     
Finance lease, liability1 
Operating lease, liability3930
Liabilities, other than long-term debt33 3636611
Deferred tax liabilities, net3131   
Deferred income tax liabilities33 
Other liabilities  55611
Other undisclosed noncurrent liabilities343349     
Total noncurrent liabilities:4163783636611
Total liabilities:605482111107672813
Stockholders' equity
Stockholders' equity attributable to parent1,154654609383474531185
Common stock0000000
Additional paid in capital2,7732,0871,6401,2221,004817324
Accumulated other comprehensive income (loss)1(0)(1)(6)1(1)(0)
Accumulated deficit(1,620)(1,433)(1,030)(833)(531)(285)(139)
Total stockholders' equity:1,154654609383474531185
TOTAL LIABILITIES AND EQUITY:1,7601,135720491541560198

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues2711045130  
Revenue, net30  
Cost of revenue
(Cost of Goods and Services Sold)
  (1)(0)   
Gross profit:2711045030  
Operating expenses(601)(528)(423)(332)(248)(148)(57)
Other undisclosed operating income  10   
Operating loss:(330)(424)(371)(329)(248)(148)(57)
Nonoperating income (expense)81241122(3)
Investment income, nonoperating713104421
Other nonoperating income (expense)1(1)(6)7(2)(0)(4)
Interest and debt expense(0)      
Loss from continuing operations before equity method investments, income taxes:(323)(412)(367)(318)(246)(146)(60)
Other undisclosed income from continuing operations before income taxes13712170    
Loss from continuing operations before income taxes:(185)(399)(197)(318)(246)(146)(60)
Income tax expense (benefit)(1)(3)(1)16(0)  
Net loss attributable to parent:(187)(403)(198)(302)(246)(146)(60)
Preferred stock dividends and other adjustments      (5)
Net loss available to common stockholders, diluted:(187)(403)(198)(302)(246)(146)(65)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(187)(403)(198)(302)(246)(146)(60)
Other comprehensive income (loss)105(7)2  
Comprehensive loss:(186)(402)(193)(309)(244)(146)(60)
Other undisclosed comprehensive loss, net of tax, attributable to parent     (1)(0)
Comprehensive loss, net of tax, attributable to parent:(186)(402)(193)(309)(244)(146)(60)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: